Alpha Cognition Inc. (ACOG) stock
Close on Nov 12, 2026Market cap $186.42MP/E –Yield –
Alpha Cognition Inc. reported revenue of $20.20M for the twelve months to Sep 30, 2026. Free cash flow was -$30.84M. At the latest close the market valued the company at $186.42M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $186.42M
- P/E ratio
- –
- Price to sales
- 9.23
- Price to book
- 3.78
- Dividend yield
- –
- Free cash flow yield
- -16.54%
Fundamentals
- Revenue
- $20.20M
- Net income
- -$29.20M
- EPS, diluted
- -$1.18
- Free cash flow
- -$30.84M
- Book value per share
- $2.26
- Diluted shares
- 22M
Trading
- Previous close
- $8.62
- Open
- $8.62
- Day's range
- $8.44 – $9.04
- Volume
- 139,197
- Average volume (20 days)
- 106,270
- Beta (5 years)
- 0.34
- 52-week range
- $4.50 – $10.14
- RSI (14 days)
- 49.7
- Volatility (1 year)
- 62.8%
- Relative volume
- 1.06×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ACOG | S&P 500 | Difference | ACOG per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.2% | -2.7% | −0.5 pts | ||
| 3 months | -4.4% | -1.7% | −2.6 pts | ||
| Year to date | +31.7% | +11.9% | +19.8 pts | ||
| 1 year | +39.9% | +12.0% | +27.9 pts | ||
| 3 years | +32.7% | +78.2% | −45.5 pts | +9.9% | +21.2% |
| 5 years | -63.2% | +73.2% | −136.4 pts | -18.1% | +11.6% |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Alpha Cognition filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- News
- News
- News
- News
About Alpha Cognition
Biological Products, (No Diagnostic Substances)
Alpha Cognition Inc. is a biopharmaceutical company that develops and commercializes therapies for neurodegenerative conditions, primarily Alzheimer’s disease. Its principal commercial offering is ZUNVEYL, an oral delayed-release tablet indicated for adults suffering from mild to moderate Alzheimer’s dementia. The company also pursues preclinical programs combining ZUNVEYL with memantine and developing sublingual formulations for cognitive impairment following mild traumatic brain injuries. Its target market comprises long-term care facilities, including nursing home physicians, healthcare teams, consultant pharmacists, and institutional pharmacies that care for elderly patients.
Company profile, executives and historyAlpha Cognition stock: common questions
What is Alpha Cognition's stock price?
ACOG closed at $8.56 on Nov 12, 2026, down 0.70% on the day. Over the past 52 weeks it traded between $4.50 and $10.14.
What is Alpha Cognition's market cap?
Alpha Cognition was worth $186.42M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ACOG's P/E ratio?
Alpha Cognition lost money over fiscal 2025 (diluted EPS -$1.18), so it has no meaningful P/E ratio.
How much revenue does Alpha Cognition make?
Alpha Cognition reported revenue of $20.20M for the twelve months to Sep 30, 2026.
Does Alpha Cognition pay a dividend?
No. Alpha Cognition has not paid a cash dividend over the last twelve months.
How has ACOG stock performed over the past year?
Including dividends, ACOG returned +39.9% over the past year, against +12.0% for the S&P 500.
How many ACOG shares are sold short?
0M shares were sold short at the latest FINRA report, 2.00% of the float, or 4.0 days of average trading volume.
Who are Alpha Cognition's competitors?
Companies most similar to Alpha Cognition by business, industry and size include LENZ, VYGR, XFOR, SCLX, LCTX.
See a number that looks wrong?